Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies
-
Abstract Number: 737
Hydroxychloroquine Whole Blood Levels Do Not Associate with Hydroxychloroquine Retinopathy
-
Abstract Number: 738
Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 739
Safety and Efficacy of Rituximab in the Treatment of Refractory Systemic Lupus Erythematosus: Results from a National Register
-
Abstract Number: 740
Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment
-
Abstract Number: 741
Hydroxychloroquine Is Not Associated with Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Patients
-
Abstract Number: 742
A Pivotal Phase III, Randomized, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan, and South Korea
-
Abstract Number: 743
Long-Term Hydroxychloroquine Therapy and Low-Dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 744
Factors Related to Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 746
Discrepancy in Rituximab-Induced B-Cell Depletion in Peripheral Blood and the Kidney and Relationship with Clinical Response in Patients with Lupus Nephritis
-
Abstract Number: 747
The Long-Term Outcomes on Leflunomide Treatment in Patients with Lupus Nephritis: A Twelve-Year Follow-up Study
-
Abstract Number: 748
A Phase 4, Multicenter, Randomized, Open-Label Study to Evaluate the Effect of Belimumab on Vaccine Responses in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 749
Evaluation of the Efficacy, Safety, and Tolerability of BIIB023 As an Adjunct to Standard of Care in Subjects with Lupus Nephritis
-
Abstract Number: 750
Predictors of Corticosteroid Use in the Systemic Lupus International Collaborating Clinics Inception Cohort – a Multivariate Analysis
-
Abstract Number: 752
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
-
Abstract Number: 753
Vitamin D Improves Systolic Blood Pressure in SLE
-
Abstract Number: 754
The Duration of Anti-Malarial Agent Intake in the First 5 Years of the Disease and Prognosis in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 755
Hydroxychloroquine Blood Level Monitoring in a Predominantly Hispanic Systemic Lupus Erythematosus Cohort
-
Abstract Number: 756
Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients
-
Abstract Number: 758
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
-
Abstract Number: 759
Gene Signature for Glucocorticoid, from in Vitro to In Vivo
-
Abstract Number: 760
Effects of Type I Interferon Inhibition on Blood Leukocyte Subsets in Patients Treated in a Phase IIb Clinical Study of Anifrolumab in SLE
-
Abstract Number: 761
Exposure-Response Analysis for Selection of Optimal Dosage Regimen of Anifrolumab in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 762
Pragmatic Treatment of Patients with Systemic Lupus Erythematosus with Rituximab: Long-Term Effects on Serum Immunoglobulins
-
Abstract Number: 763
Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 764
Atacicept: Integrated Safety Profile from Phase II Randomized Placebo-Controlled Studies in Autoimmune Diseases
-
Abstract Number: 765
High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
-
Abstract Number: 766
Withdrawal of Mycophenolate Mofetil after Maintenance Treatment of SLE Nephritis Associated with Renal Relapse
-
Abstract Number: 767
Hydroxychloroquine Induced Retinopathy in SLE
-
Abstract Number: 768
7-Year Safety and Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus
-
Abstract Number: 769
Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort
-
Abstract Number: 770
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
-
Abstract Number: 771
Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE
-
Abstract Number: 772
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
-
Abstract Number: 773
Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis
-
Abstract Number: 775
Evaluation of Use of Belimumab in Clinical Practice Settings: Results in Argentina
-
Abstract Number: 776
Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique
-
Abstract Number: 777
a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus
-
Abstract Number: 779
Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus
-
Abstract Number: 780
Belimumab Use in African-American Patients in an U.S. Academic Medical Center
-
Abstract Number: 781
The Use of Rituximab in Newly Diagnosed Systemic Lupus Erythematosus Patients: Long Term Steroid Saving Capacity and Clinical Effectiveness
-
Abstract Number: 782
Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review
-
Abstract Number: 783
Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE
-
Abstract Number: 784
Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE
-
Abstract Number: 785
What Is the Prevalence of Cognitive Impairment in Lupus and Which Instruments Are Used to Measure It? a Systematic Review and Meta-Analysis
-
Abstract Number: 786
Complement Split Product iC3b and C3 Blood Levels Best Associate with Active and Clinically Meaningful Changes in SLE Disease Activity
-
Abstract Number: 787
Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
-
Abstract Number: 788
Unresolving C4 Hypocomplementemia Associates with a Different Spectrum of Disease in SLE and Is More Important Than Transiently Low Levels
-
Abstract Number: 789
Use of Nominal Group Technique to Determine Candidate Items for SLE Classification Criteria Development
-
Abstract Number: 790
Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) – an Expert Opinion Case Study
-
Abstract Number: 791
The International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns (ICAP) Initiative – Update and Its Impact
-
Abstract Number: 792
Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate to Severe SLE
-
Abstract Number: 793
Multi-Parametric Model Development for Assessing Lupus Nephritis and Disease Activity
-
Abstract Number: 794
Development and Initial Validation of a Novel Lupus Disease Activity Index to Account for Glucocorticoids: Sledai-2K Glucocorticoids Index (SGI)
-
Abstract Number: 795
Low Disease Activity in Systemic Lupus Erythematosus: An Achievable Goal?